Combined treatment with tamoxifen and a fusicoccin derivative (ISIR-042) to overcome resistance to therapy and to enhance the antitumor activity of 5-fluorouracil and gemcitabine in pancreatic cancer cells

International Journal of Oncology

Volumn 47, Issue 1, 2015, Pages 315-324

  Miyake, Takaaki ^a   Honma, Yoshio ^a   Urano, Takeshi ^a   Kato, Nobuo ^b   Suzumiya, Junji ^a  

^a SHIMANE UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Fusicoccin derivative; Lipid peroxidation; Pancreatic cancer cells; Tamoxifen; Xenograft

Indexed keywords

ALPHA TOCOPHEROL; CYTOCHROME C; FLUOROURACIL; FUSICOCCIN; GEMCITABINE; TAMOXIFEN; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DITERPENE; GLYCOSIDE; ISIR-042;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BODY WEIGHT; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CANCER SURVIVAL; CELL GROWTH; COLONY FORMATION; DRUG EFFECT; DRUG POTENTIATION; GENE EXPRESSION; HUMAN; HUMAN CELL; LIPID PEROXIDATION; MEMBRANE STABILIZATION; OVERALL SURVIVAL; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; FEMALE; METABOLISM; MOUSE; NUDE MOUSE; PANCREATIC NEOPLASMS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYCYTIDINE; DITERPENES; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; FLUOROURACIL; GLYCOSIDES; HUMANS; LIPID PEROXIDATION; MICE; MICE, NUDE; PANCREATIC NEOPLASMS; TAMOXIFEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84931076447     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2015.2979     Document Type: Article

References (37)

1. Evance DB, Abbruzzes JL and Rich TA: Cancer of the pancreas. In: Cancer, Principles and Practice of Oncology. DeVita VT Jr, Hellman S and Rosenberg SA (eds). J.B. Lippincott Co., Philadelphia, pp1054-1087, 1997.
2. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
3. Conroy T, Desseigne F, Ychou M., Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, et al.; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364: 1817-1825, 2011.
4. Bozic I, Reiter JG, Allen B, Antal T., Chatterjee K, Shah P, Moon Y.S., Yaqubie A., Kelly N, Le DT, et al.: Evolutionary dynamics of cancer in response to targeted combination therapy. eLife 2: e00747, 2013.
5. Kawakami K, Hattori M, Inoue T., Maruyama Y, Ohkanda J, Kato N., Tongu M, Yamada T, Akimoto M, Takenaga K, et al.: A novel fusicoccin derivative preferentially targets hypoxic tumor cells and inhibits tumor growth in xenografts. Anticancer Agents Med Chem 12: 791-800, 2012.
6. Mandlekar S and Kong ANT: Mechanisms of tamoxifen-induced apoptosis. Apoptosis 6: 469-477, 2001.
7. Avgeropoulos NG and Batchelor TT: New treatment strategies for malignant gliomas. Oncologist 4: 209-224, 1999
8. Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55, 1984
9. Buege JA and Aust SD: Microsomal lipid peroxidation. Methods Enzymol 52: 302-310, 1978.
10. Tian Y, Ding W, Wang Y., Ji T, Sun S, Mo Q., Chen P, Fang Y, Liu J, Wang B, et al.: Ubiquitin B in cervical cancer: Critical for the maintenance of cancer stem-like cell characters. PLoS One 8: e84457, 2013.
11. Hattori M, Kawakami K, Akimoto M., Takenaga K, Suzumiya J and Honma Y Antitumor effect of Japanese apricot extract (MK615) on human cancer cells in vitro and in vivo through a reactive oxygen species-dependent mechanism. Tumori 99: 239-248, 2013.
12. Kohli L, Kaza N, Coric T., Byer SJ, Brossier NM, Klocke BJ, Bjornsti M.A., Carroll SL and Roth KA: 4-Hydroxytamoxifen induces autophagic death through K-Ras degradation. Cancer Res 73: 4395-4405, 2013.
13. Morad SAF, Levin JC, Tan S-F, Fox TE, Feith DJ and Cabot MC: Novel off-target effect of tamoxifen - inhibition of acid ceramidase activity in cancer cells. Biochim Biophys Acta 1831: 1657-1664, 2013.
14. Hezel AF, Kimmelman AC, Stanger B.Z., Bardeesy N and Depinho RA: Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 20: 1218-1249, 2006.
15. Maccarrone M, Fantini C, Ranalli M., Melino G and Agrö AF: Activation of nitric oxide synthase is involved in tamoxifen-induced apoptosis of human erythroleukemia K562 cells. FEBS Lett 434: 421-424, 1998.
16. Nazarewicz RR, Zenebe WJ, Parihar A, Larson S.K., Alidema E., Choi J and Ghafourifar P: Tamoxifen induces oxidative stress and mitochondrial apoptosis via stimulating mitochondrial nitric oxide synthase. Cancer Res 67: 1282-1290, 2007
17. Atkinson J, Harroun T, Wassail S.R., Stillwell W and Katsaras J: The location and behavior of alpha-tocopherol in membranes. Mol Nutr Food Res 54: 641-651, 2010.
18. Ghafourifar P, Schenk U, Klein SD and Richter C: Mitochondrial nitric-oxide synthase stimulation causes cytochrome c release from isolated mitochondria. Evidence for intramitochondrial peroxynitrite formation. J Biol Chem 274: 31185-31188, 1999
19. Radi R, Beekman JS, Bush KM and Freeman BA: Peroxynitrite-induced membrane lipid peroxidation: The cytotoxic potential of superoxide and nitric oxide. Arch Biochem Biophys 288: 481-487, 1991.
20. Li C, Heidt DG, Dalerba P, Burant C.F., Zhang L., Adsay V, Wicha M, Clarke MF and Simeone DM: Identification of pancreatic cancer stem cells. Cancer Res 67: 1030-1037, 2007
21. Lee CJ, Li C and Simeone DM: Human pancreatic cancer stem cells: Implications for how we treat pancreatic cancer. Transi Oncol 1: 14-18, 2008.
22. Honma Y, Ishii Y, Yamamoto-Yamaguchi Y, Sassa T and Asahi K: Cotylenin A, a differentiation-inducing agent, and IFN-alpha cooperatively induce apoptosis and have an antitumor effect on human non-small cell lung carcinoma cells in nude mice. Cancer Res 63: 3659-3666, 2003.
23. Oecking C, Eckerskorn C and Weiler EW: The fusicoccin receptor of plants is a member of the 14-3-3 superfamily of eukaryotic regulatory proteins. FEBS Lett 352: 163-166, 1994
24. Seimiya H, Sawada H, Muramatsu Y., Shimizu M, Ohko K, Yamane K and Tsuruo T: Involvement of 14-3-3 proteins in nuclear localization of telomerase. EMBO J 19: 2652-2661, 2000.
25. Rittinger K, Budman J, Xu J., Volinia S, Cantley LC, Smerdon S.J., Gamblin SJ and Yaffe MB: Structural analysis of 14-3-3 phos-phopeptide complexes identifies a dual role for the nuclear export signal of 14-3-3 in ligand binding. Mol Cell 4: 153-166, 1999
26. Fujita N, Saito S and Tsuruo T: Phosphorylation of p27Kipl at threonine 198 by p90 ribosomal protein S6 kinase promotes its binding to 14-3-3 and cytoplasmic localization. J Biol Chem 278: 49254-49260, 2003.
27. Molzan M, Kasper S, Röglin L, Skwarczynska M., Sassa T, Inoue T, Breitenbuecher F., Ohkanda J, Kato N, Schuier M, et al.: Stabilization of physical RAF/14-3-3 interaction by cotylenin A as treatment strategy for RAS mutant cancers. ACS Chem Biol 8: 1869-1875, 2013.
28. Lu Y, Zhu H, Shan H., Lu J, Chang X, Li X., Lu J, Fan X, Zhu S, Wang Y, et al.: Knockdown of Oct4 and Nanog expression inhibits the sternness of pancreatic cancer cells. Cancer Lett 340: 113-123, 2013.
29. Herreros-Villanueva M, Bujanda L, Billadeau DD and Zhang J-S: Embryonic stem cell factors and pancreatic cancer. World J Gastroenterol 20: 2247-2254, 2014
30. Greenway B, Iqbal MJ, Johnson PJ and Williams R: Oestrogen receptor proteins in malignant and fetal pancreas. Br Med J (Clin Res Ed) 283: 751-753, 1981.
31. Benz C, Hollander C and Miller B: Endocrine-responsive pancreatic carcinoma: Steroid binding and cytotoxicity studies in human tumor cell lines. Cancer Res 46: 2276-2281, 1986.
32. Singh S, Baker PR, Poulsom R, Wright N.A., Sheppard MC, Langman MJ and Neoptolemos JP: Expression of oestrogen receptor and oestrogen-inducible genes in pancreatic cancer. Br J Surg 84: 1085-1089, 1997
33. Mikulski S: Tamoxifen in patients with advanced pancreatic adenocarcinoma. Oncol Rep 3: 17-19, 1996.
34. Horimi T, Takasaki M, Toki A., Nishimura W and Morita S: The beneficial effect of tamoxifen therapy in patients with resected adenocarcinoma of the pancreas. Hepatogastroenterology 43: 1225-1229, 1996.
35. Lamy R, Conroy T, Brunaud L and Bresier L: Tamoxifen for metastatic pancreatic adenocarcinoma: A complete response. Gastroenterol Clin Biol 25: 912-913, 2001 (In French).
36. Eckel F, Lersch C, Lippl F., Assmann G and Schulte-Frohlinde E: Phase II trial of cyclophosphamide, leucovorin, 5-fluorouracil 24-hour infusion and tamoxifen in pancreatic cancer. J Exp Clin Cancer Res 19: 295-300, 2000.
37. Tomao S, Romiti A, Massidda B., Ionta MT, Farris A, Zullo A, Brescia A., Santuari L and Frati L: A phase II study of gemcitabine and tamoxifen in advanced pancreatic cancer. Anticancer Res 22: 2361-2364, 2002.